{"transactions":[{"id":746885,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37305,"kind":"person","name":"Kiper Christopher S","position":1,"cik":"0001432744","reported_name":"Kiper Christopher S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37299,"kind":"person","name":"Legion Partners Asset Management, LLC","position":2,"cik":"0001560207","reported_name":"Legion Partners Asset Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37300,"kind":"person","name":"Legion Partners, L.P. I","position":3,"cik":"0001595909","reported_name":"Legion Partners, L.P. I","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37301,"kind":"person","name":"Legion Partners, L.P. II","position":4,"cik":"0001618783","reported_name":"Legion Partners, L.P. II","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37303,"kind":"person","name":"Legion Partners, LLC","position":5,"cik":"0001682390","reported_name":"Legion Partners, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37304,"kind":"person","name":"Legion Partners Holdings, LLC","position":6,"cik":"0001682389","reported_name":"Legion Partners Holdings, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37298,"kind":"person","name":"White Raymond T.","position":7,"cik":"0001682494","reported_name":"White Raymond T.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:37:03.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Legion Partners, L.P. I (\"Legion Partners I\"), Legion Partners, L.P. II (\"Legion Partners II\"), Legion Partners, LLC (\"General Partner\"), Legion Partners Asset Management, LLC (\"Legion Partners Asset Management\"), Legion Partners Holdings, LLC (\"Legion Partners Holdings\"), Christopher S. Kiper and Raymond White (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that owns more than 10% of Lifecore Biomedical, Inc.'s (the \"Issuer\") outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"kind","element":"transactionCoding","label":"F4","text":"These securities are RSUs granted to Mr. Kiper, a member of the Issuer's Board of Directors (the \"Board\") in respect of his service on the Board. Mr. Kiper holds these RSUs for the benefit of Legion Partners Asset Management. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions. As of the date hereof, 58,069 RSUs have vested."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The securities held by Mr. Kiper as described in footnotes (4) and (5) are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units (\"RSUs\") convert into Common Stock of the Issuer on a 1 for 1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Issuer first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The restricted stock units (\"RSUs\") convert into Common Stock of the Issuer on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Issuer first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"These securities are RSUs granted to Mr. Kiper, a member of the Issuer's Board of Directors (the \"Board\") in respect of his service on the Board. Mr. Kiper holds these RSUs for the benefit of Legion Partners Asset Management. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions. As of the date hereof, 58,069 RSUs have vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The securities held by Mr. Kiper as described in footnotes (4) and (5) are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are RSUs granted to Mr. Kiper, a member of the Issuer's Board of Directors (the \"Board\") in respect of his service on the Board. Mr. Kiper holds these RSUs for the benefit of Legion Partners Asset Management. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions. As of the date hereof, 58,069 RSUs have vested."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities held by Mr. Kiper as described in footnotes (4) and (5) are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."}],"balance_after":103482,"source":{"system":"sec-edgar","filing":"0000921895-26-001575","document":"form409050032_06082026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000092189526001575/form409050032_06082026.xml","form_type":"4"}},{"id":748683,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41100,"kind":"person","name":"OBUS NELSON","position":1,"cik":"0001017043","reported_name":"OBUS NELSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:47:24.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."}],"balance_after":164100,"source":{"system":"sec-edgar","filing":"0001017043-26-000002","document":"wk-form4_1780692442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000101704326000002/wk-form4_1780692442.xml","form_type":"4"}},{"id":748684,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:46:35.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."}],"balance_after":69967,"source":{"system":"sec-edgar","filing":"0001376960-26-000002","document":"wk-form4_1780692392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000137696026000002/wk-form4_1780692392.xml","form_type":"4"}},{"id":748682,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41099,"kind":"person","name":"Schechter Joshua","position":1,"cik":"0001336601","reported_name":"Schechter Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:46:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."}],"balance_after":133080,"source":{"system":"sec-edgar","filing":"0001336601-26-000004","document":"wk-form4_1780692374.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000133660126000004/wk-form4_1780692374.xml","form_type":"4"}},{"id":748681,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37594,"kind":"person","name":"Korenberg Matthew E","position":1,"cik":"0001649903","reported_name":"Korenberg Matthew E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:46:02.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."}],"balance_after":69967,"source":{"system":"sec-edgar","filing":"0001649903-26-000002","document":"wk-form4_1780692359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000164990326000002/wk-form4_1780692359.xml","form_type":"4"}},{"id":748680,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41098,"kind":"person","name":"Antunes Humberto Calheiros","position":1,"cik":"0001800145","reported_name":"Antunes Humberto Calheiros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:45:19.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."}],"balance_after":72967,"source":{"system":"sec-edgar","filing":"0001800145-26-000002","document":"wk-form4_1780692316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000180014526000002/wk-form4_1780692316.xml","form_type":"4"}},{"id":748679,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41097,"kind":"person","name":"Johnson Paul Harold","position":1,"cik":"0002034858","reported_name":"Johnson Paul Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:45:04.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."}],"balance_after":69967,"source":{"system":"sec-edgar","filing":"0002034858-26-000002","document":"wk-form4_1780692301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000203485826000002/wk-form4_1780692301.xml","form_type":"4"}},{"id":748677,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41095,"kind":"person","name":"HOUDE LOVAS KATRINA","position":1,"cik":"0001269294","reported_name":"HOUDE LOVAS KATRINA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:44:09.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":25907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026)."}],"balance_after":135319,"source":{"system":"sec-edgar","filing":"0001269294-26-000002","document":"wk-form4_1780692247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000126929426000002/wk-form4_1780692247.xml","form_type":"4"}},{"id":768769,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-21T20:28:13.000Z","date":"2026-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":40413,"price":4.57,"value":184687.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting."}],"balance_after":592915,"source":{"system":"sec-edgar","filing":"0002022547-26-000003","document":"wk-form4_1779395291.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000202254726000003/wk-form4_1779395291.xml","form_type":"4"}},{"id":807618,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Common Stock","published_at":"2026-04-16T20:39:35.000Z","date":"2026-04-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":24645,"price":5.2,"value":128154.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting."}],"balance_after":246333,"source":{"system":"sec-edgar","filing":"0002062209-26-000004","document":"wk-form4_1776371972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000206220926000004/wk-form4_1776371972.xml","form_type":"4"}},{"id":875274,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Common Stock","published_at":"2026-03-02T23:52:42.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted Stock Units will vest on the 3rd anniversary of the grant date."}],"balance_after":270978,"source":{"system":"sec-edgar","filing":"0002062209-26-000002","document":"wk-form4_1772495559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000206220926000002/wk-form4_1772495559.xml","form_type":"4"}},{"id":1048620,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-04T20:42:03.000Z","date":"2025-09-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":22932,"price":7.71,"value":176805.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting."}],"balance_after":336691,"source":{"system":"sec-edgar","filing":"0001005286-25-000120","document":"wk-form4_1757018519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000120/wk-form4_1757018519.xml","form_type":"4"}},{"id":1085911,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41100,"kind":"person","name":"OBUS NELSON","position":1,"cik":"0001017043","reported_name":"OBUS NELSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T22:48:53.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than\n50 weeks from the date hereof)."}],"balance_after":138193,"source":{"system":"sec-edgar","filing":"0001005286-25-000094","document":"wk-form4_1752792527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000094/wk-form4_1752792527.xml","form_type":"4"}},{"id":1085910,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37305,"kind":"person","name":"Kiper Christopher S","position":1,"cik":"0001432744","reported_name":"Kiper Christopher S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37299,"kind":"person","name":"Legion Partners Asset Management, LLC","position":2,"cik":"0001560207","reported_name":"Legion Partners Asset Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37300,"kind":"person","name":"Legion Partners, L.P. I","position":3,"cik":"0001595909","reported_name":"Legion Partners, L.P. I","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37301,"kind":"person","name":"Legion Partners, L.P. II","position":4,"cik":"0001618783","reported_name":"Legion Partners, L.P. II","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37303,"kind":"person","name":"Legion Partners, LLC","position":5,"cik":"0001682390","reported_name":"Legion Partners, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37304,"kind":"person","name":"Legion Partners Holdings, LLC","position":6,"cik":"0001682389","reported_name":"Legion Partners Holdings, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37298,"kind":"person","name":"White Raymond T.","position":7,"cik":"0001682494","reported_name":"White Raymond T.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T22:36:53.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Legion Partners, L.P. I (\"Legion Partners I\"), Legion Partners, L.P. II (\"Legion Partners II\"), Legion Partners, LLC (\"General Partner\"), Legion Partners Asset Management, LLC (\"Legion Partners Asset Management\"), Legion Partners Holdings, LLC (\"Legion Partners Holdings\"), Christopher S. Kiper and Raymond White (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that owns more than 10% of Lifecore Biomedical, Inc.'s (the \"Issuer\") outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"kind","element":"transactionCoding","label":"F4","text":"These securities are RSUs granted to Mr. Kiper, a member of the Issuer's Board of Directors (the \"Board\") in respect of his service on the Board. Mr. Kiper holds these RSUs for the benefit of Legion Partners Asset Management. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions. As of the date hereof, 58,069 RSUs have vested."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The securities held by Mr. Kiper as described in footnotes (4) and (5) are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units (\"RSUs\") convert into Common Stock of the Issuer on a 1 for 1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2026 (provided such date is no less than 50 weeks from grant date)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The restricted stock units (\"RSUs\") convert into Common Stock of the Issuer on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2026 (provided such date is no less than 50 weeks from grant date)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"These securities are RSUs granted to Mr. Kiper, a member of the Issuer's Board of Directors (the \"Board\") in respect of his service on the Board. Mr. Kiper holds these RSUs for the benefit of Legion Partners Asset Management. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions. As of the date hereof, 58,069 RSUs have vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The securities held by Mr. Kiper as described in footnotes (4) and (5) are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities are RSUs granted to Mr. Kiper, a member of the Issuer's Board of Directors (the \"Board\") in respect of his service on the Board. Mr. Kiper holds these RSUs for the benefit of Legion Partners Asset Management. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions. As of the date hereof, 58,069 RSUs have vested."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities held by Mr. Kiper as described in footnotes (4) and (5) are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."}],"balance_after":77575,"source":{"system":"sec-edgar","filing":"0000921895-25-002006","document":"form409050032_07172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000092189525002006/form409050032_07172025.xml","form_type":"4"}},{"id":1085909,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41097,"kind":"person","name":"Johnson Paul Harold","position":1,"cik":"0002034858","reported_name":"Johnson Paul Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:45:24.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than 50 weeks from the date hereof)."}],"balance_after":44060,"source":{"system":"sec-edgar","filing":"0001005286-25-000092","document":"wk-form4_1752785118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000092/wk-form4_1752785118.xml","form_type":"4"}},{"id":1085908,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:43:03.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than\n50 weeks from the date hereof)."}],"balance_after":44060,"source":{"system":"sec-edgar","filing":"0001005286-25-000091","document":"wk-form4_1752784972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000091/wk-form4_1752784972.xml","form_type":"4"}},{"id":1085907,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37594,"kind":"person","name":"Korenberg Matthew E","position":1,"cik":"0001649903","reported_name":"Korenberg Matthew E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:41:57.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than\n50 weeks from the date hereof)."}],"balance_after":44060,"source":{"system":"sec-edgar","filing":"0001005286-25-000090","document":"wk-form4_1752784888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000090/wk-form4_1752784888.xml","form_type":"4"}},{"id":1085906,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41098,"kind":"person","name":"Antunes Humberto Calheiros","position":1,"cik":"0001800145","reported_name":"Antunes Humberto Calheiros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:40:37.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than\n50 weeks from the date hereof)."}],"balance_after":47060,"source":{"system":"sec-edgar","filing":"0001005286-25-000089","document":"wk-form4_1752784823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000089/wk-form4_1752784823.xml","form_type":"4"}},{"id":1085905,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41099,"kind":"person","name":"Schechter Joshua","position":1,"cik":"0001336601","reported_name":"Schechter Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:39:07.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than\n50 weeks from the date hereof)."}],"balance_after":107173,"source":{"system":"sec-edgar","filing":"0001005286-25-000088","document":"wk-form4_1752784730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000088/wk-form4_1752784730.xml","form_type":"4"}},{"id":1085902,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41095,"kind":"person","name":"HOUDE LOVAS KATRINA","position":1,"cik":"0001269294","reported_name":"HOUDE LOVAS KATRINA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-17T20:36:29.000Z","date":"2025-07-15","kind":"grant","planned":false,"acquired":true,"shares":19506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than\n50 weeks from the date hereof)."}],"balance_after":109412,"source":{"system":"sec-edgar","filing":"0001005286-25-000087","document":"wk-form4_1752784568.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000087/wk-form4_1752784568.xml","form_type":"4"}},{"id":1089673,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2025-07-10T20:45:45.000Z","date":"2025-07-08","kind":"exercise","planned":false,"acquired":false,"shares":37000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."}],"balance_after":333000,"derivative":{"expiration_date":"2030-04-14","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001005286-25-000080","document":"wk-form4_1752180336.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000080/wk-form4_1752180336.xml","form_type":"4"}},{"id":1089672,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Common Stock","published_at":"2025-07-10T20:45:45.000Z","date":"2025-07-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":11022,"price":8.19,"value":90270.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the performance stock unit award as reported in\nTable I."}],"balance_after":240978,"source":{"system":"sec-edgar","filing":"0001005286-25-000080","document":"wk-form4_1752180336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000080/wk-form4_1752180336.xml","form_type":"4"}},{"id":1089671,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Common Stock","published_at":"2025-07-10T20:45:45.000Z","date":"2025-07-08","kind":"exercise","planned":false,"acquired":true,"shares":37000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."}],"balance_after":252000,"source":{"system":"sec-edgar","filing":"0001005286-25-000080","document":"wk-form4_1752180336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000080/wk-form4_1752180336.xml","form_type":"4"}},{"id":1089670,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2025-07-10T20:42:57.000Z","date":"2025-07-08","kind":"exercise","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."}],"balance_after":600000,"derivative":{"expiration_date":"2029-09-03","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001005286-25-000079","document":"wk-form4_1752180146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000079/wk-form4_1752180146.xml","form_type":"4"}},{"id":1089669,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-10T20:42:57.000Z","date":"2025-07-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":32806,"price":8.19,"value":268681.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the performance stock unit award as reported in\nTable I."}],"balance_after":359623,"source":{"system":"sec-edgar","filing":"0001005286-25-000079","document":"wk-form4_1752180146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000079/wk-form4_1752180146.xml","form_type":"4"}},{"id":1089668,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-10T20:42:57.000Z","date":"2025-07-08","kind":"exercise","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."}],"balance_after":392429,"source":{"system":"sec-edgar","filing":"0001005286-25-000079","document":"wk-form4_1752180146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000079/wk-form4_1752180146.xml","form_type":"4"}},{"id":1089667,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2025-07-10T20:41:00.000Z","date":"2025-07-08","kind":"exercise","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."}],"balance_after":1350000,"derivative":{"expiration_date":"2029-05-20","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001005286-25-000078","document":"wk-form4_1752180022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000078/wk-form4_1752180022.xml","form_type":"4"}},{"id":1089666,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-10T20:41:00.000Z","date":"2025-07-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":54857,"price":8.19,"value":449278.83,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the performance stock unit award as reported in\nTable I."}],"balance_after":633328,"source":{"system":"sec-edgar","filing":"0001005286-25-000078","document":"wk-form4_1752180022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000078/wk-form4_1752180022.xml","form_type":"4"}},{"id":1089665,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-10T20:41:00.000Z","date":"2025-07-08","kind":"exercise","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices."}],"balance_after":688185,"source":{"system":"sec-edgar","filing":"0001005286-25-000078","document":"wk-form4_1752180022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000078/wk-form4_1752180022.xml","form_type":"4"}},{"id":1132468,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T00:06:01.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":150419,"price":7.1238,"value":1071554.8722,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.9000 to $7.5000, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":264180,"source":{"system":"sec-edgar","filing":"0000950170-25-078524","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025078524/ownership.xml","form_type":"4"}},{"id":1132467,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T00:06:01.000Z","date":"2025-05-27","kind":"sale","planned":false,"acquired":false,"shares":1139504,"price":6.5042,"value":7411561.9168,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.500 to $6.900, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":414599,"source":{"system":"sec-edgar","filing":"0000950170-25-078524","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025078524/ownership.xml","form_type":"4"}},{"id":1132466,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-29T00:06:01.000Z","date":"2025-05-23","kind":"sale","planned":false,"acquired":false,"shares":96137,"price":6.7548,"value":649386.2076,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.7500 to $6.7800, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":1554103,"source":{"system":"sec-edgar","filing":"0000950170-25-078524","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025078524/ownership.xml","form_type":"4"}},{"id":1138047,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-22T17:43:07.000Z","date":"2025-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":21532,"price":6.63,"value":142757.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with an RSU vesting."}],"balance_after":538185,"source":{"system":"sec-edgar","filing":"0001005286-25-000074","document":"wk-form4_1747935780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000074/wk-form4_1747935780.xml","form_type":"4"}},{"id":1146110,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-16T15:28:11.000Z","date":"2025-05-13","kind":"sale","planned":false,"acquired":false,"shares":12334,"price":7.0012,"value":86352.8008,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0100, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":1650240,"source":{"system":"sec-edgar","filing":"0000950170-25-073196","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025073196/ownership.xml","form_type":"4"}},{"id":1152763,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-12T22:58:37.000Z","date":"2025-05-12","kind":"sale","planned":false,"acquired":false,"shares":45698,"price":7.0337,"value":321426.0226,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.1800, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":1662574,"source":{"system":"sec-edgar","filing":"0000950170-25-069576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025069576/ownership.xml","form_type":"4"}},{"id":1152762,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-12T22:58:37.000Z","date":"2025-05-09","kind":"sale","planned":false,"acquired":false,"shares":700,"price":7,"value":4900.0,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":1708272,"source":{"system":"sec-edgar","filing":"0000950170-25-069576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025069576/ownership.xml","form_type":"4"}},{"id":1152761,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-12T22:58:37.000Z","date":"2025-05-08","kind":"sale","planned":false,"acquired":false,"shares":5098,"price":7.0014,"value":35693.1372,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0010, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":1708972,"source":{"system":"sec-edgar","filing":"0000950170-25-069576","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025069576/ownership.xml","form_type":"4"}},{"id":1156545,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-08T01:09:18.000Z","date":"2025-05-07","kind":"sale","planned":false,"acquired":false,"shares":15847,"price":7.0107,"value":111098.5629,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0700, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":1714070,"source":{"system":"sec-edgar","filing":"0000950170-25-066222","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025066222/ownership.xml","form_type":"4"}},{"id":1156544,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-08T01:09:18.000Z","date":"2025-05-06","kind":"sale","planned":false,"acquired":false,"shares":701,"price":7.0472,"value":4940.0872,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.1100, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":1729917,"source":{"system":"sec-edgar","filing":"0000950170-25-066222","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025066222/ownership.xml","form_type":"4"}},{"id":1156543,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":54488,"kind":"person","name":"English Aron R.","position":1,"cik":"0001770436","reported_name":"English Aron R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54489,"kind":"organization","name":"22NW, LP","position":2,"cik":"0001694297","reported_name":"22NW, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54490,"kind":"organization","name":"22NW Fund, LP","position":3,"cik":"0001640809","reported_name":"22NW Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54491,"kind":"organization","name":"22NW Fund GP, LLC","position":4,"cik":"0001770575","reported_name":"22NW Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54492,"kind":"organization","name":"22NW GP, Inc.","position":5,"cik":"0001783663","reported_name":"22NW GP, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-08T01:09:18.000Z","date":"2025-05-05","kind":"sale","planned":false,"acquired":false,"shares":24543,"price":7.0827,"value":173830.7061,"ownership":{"direct":false,"nature":"By: 22NW Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by 22NW Fund, LP (\"22NW Fund\"), 22NW, LP (\"22NW\"), 22NW Fund GP, LLC (\"22NW GP\"), 22NW GP, Inc. (\"22NW Inc.\") and Aron English (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.3650, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities owned directly by 22NW Fund. As the investment manager to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW Fund, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW Inc. may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW, Manager of 22NW GP and President and sole shareholder of 22NW Inc., may be deemed to beneficially own the securities owned directly by 22NW Fund."}],"balance_after":1730618,"source":{"system":"sec-edgar","filing":"0000950170-25-066222","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000095017025066222/ownership.xml","form_type":"4"}},{"id":1171242,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2025-04-16T20:38:47.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":210000,"derivative":{"exercise_price":6.17,"exercise_date":"2026-04-14","expiration_date":"2032-04-14","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001005286-25-000070","document":"wk-form4_1744835921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000070/wk-form4_1744835921.xml","form_type":"4"}},{"id":1171241,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2025-04-16T20:38:47.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":370000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock prices."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones."}],"balance_after":0,"derivative":{"expiration_date":"2030-04-14","underlying":"Common Stock","underlying_shares":370000},"source":{"system":"sec-edgar","filing":"0001005286-25-000070","document":"wk-form4_1744835921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000070/wk-form4_1744835921.xml","form_type":"4"}},{"id":1171240,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Common Stock","published_at":"2025-04-16T20:38:47.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":170000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":215000,"source":{"system":"sec-edgar","filing":"0001005286-25-000070","document":"wk-form4_1744835921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000070/wk-form4_1744835921.xml","form_type":"4"}},{"id":1171239,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":52335,"kind":"person","name":"Salus Thomas D.","position":1,"cik":"0002062209","reported_name":"Salus Thomas D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal & Administration"}}],"security":"Common Stock","published_at":"2025-04-16T20:38:47.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001005286-25-000070","document":"wk-form4_1744835921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000070/wk-form4_1744835921.xml","form_type":"4"}},{"id":1307132,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-08T21:10:19.000Z","date":"2025-01-08","kind":"purchase","planned":false,"acquired":true,"shares":17000,"price":5.74,"value":97580.0,"ownership":{"direct":true},"balance_after":559717,"source":{"system":"sec-edgar","filing":"0001628280-25-000943","document":"wk-form4_1736370610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828025000943/wk-form4_1736370610.xml","form_type":"4"}},{"id":1337935,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-10T21:26:55.000Z","date":"2024-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":11769,"price":7.15,"value":84148.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the stock grant."}],"balance_after":542717,"source":{"system":"sec-edgar","filing":"0001628280-24-050620","document":"wk-form4_1733866009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024050620/wk-form4_1733866009.xml","form_type":"4"}},{"id":1337934,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-10T21:26:55.000Z","date":"2024-12-06","kind":"grant","planned":false,"acquired":true,"shares":38461,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":554486,"source":{"system":"sec-edgar","filing":"0001628280-24-050620","document":"wk-form4_1733866009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024050620/wk-form4_1733866009.xml","form_type":"4"}},{"id":1337933,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-10T21:26:15.000Z","date":"2024-12-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":5653,"price":7.15,"value":40418.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the stock grant."}],"balance_after":317429,"source":{"system":"sec-edgar","filing":"0001628280-24-050619","document":"wk-form4_1733865968.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024050619/wk-form4_1733865968.xml","form_type":"4"}},{"id":1337932,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-10T21:26:15.000Z","date":"2024-12-06","kind":"grant","planned":false,"acquired":true,"shares":19720,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":323082,"source":{"system":"sec-edgar","filing":"0001628280-24-050619","document":"wk-form4_1733865968.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024050619/wk-form4_1733865968.xml","form_type":"4"}},{"id":1380318,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-29T20:46:43.000Z","date":"2024-10-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":34138,"price":5.09,"value":173762.42,"ownership":{"direct":true},"balance_after":303362,"source":{"system":"sec-edgar","filing":"0001628280-24-044118","document":"wk-form4_1730234796.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024044118/wk-form4_1730234796.xml","form_type":"4"}},{"id":1380317,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-29T20:46:43.000Z","date":"2024-10-07","kind":"exercise","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The performance-based restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":337500,"source":{"system":"sec-edgar","filing":"0001628280-24-044118","document":"wk-form4_1730234796.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024044118/wk-form4_1730234796.xml","form_type":"4"}},{"id":1390396,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":86973,"kind":"organization","name":"WYNNEFIELD PARTNERS SMALL CAP VALUE LP I","position":1,"cik":"0001251565","reported_name":"WYNNEFIELD PARTNERS SMALL CAP VALUE LP I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86974,"kind":"organization","name":"WYNNEFIELD PARTNERS SMALL CAP VALUE LP","position":2,"cik":"0000899083","reported_name":"WYNNEFIELD PARTNERS SMALL CAP VALUE LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86975,"kind":"organization","name":"WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD","position":3,"cik":"0001030806","reported_name":"WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86976,"kind":"organization","name":"WYNNEFIELD CAPITAL MANAGEMENT LLC","position":4,"cik":"0001056835","reported_name":"WYNNEFIELD CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86977,"kind":"organization","name":"WYNNEFIELD CAPITAL INC","position":5,"cik":"0001251567","reported_name":"WYNNEFIELD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86978,"kind":"organization","name":"Wynnefield Capital, Inc. Profit Sharing Plan","position":6,"cik":"0001289453","reported_name":"Wynnefield Capital, Inc. Profit Sharing Plan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41100,"kind":"person","name":"OBUS NELSON","position":7,"cik":"0001017043","reported_name":"OBUS NELSON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86979,"kind":"person","name":"LANDES JOSHUA","position":8,"cik":"0001251568","reported_name":"LANDES JOSHUA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2024-10-07T20:45:10.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":169753,"price":4.1,"value":695987.3,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person has an indirect beneficial ownership interest in 1,344,585 shares of Common Stock, which are directly beneficially owned by Wynnefield Partners Small Cap Value, L.P., as members of a group under Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Wynnefield Partners Small Cap Value, L.P., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital Management, LLC, as the sole general partner of Wynnefield Partners Small Cap Value, L.P., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value L.P. directly beneficially owns."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Partners Small Cap Value, L.P. directly beneficially owns. Does not include 162,543 shares of Common Stock issuable upon conversion of certain shares of Convertible Preferred Stock that are immediately convertible."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person has an indirect beneficial ownership interest in 895,498 shares of Common Stock, which are directly beneficially owned by Wynnefield Small Cap Value Offshore Fund, Ltd., as members of a group under Section 13(d) of the Exchange Act. Wynnefield Small Cap Value Offshore Fund, Ltd., which maintains offices at the same address as the Reporting Person, is filing this statement jointly with the Reporting Person. Wynnefield Capital, Inc. as the sole investment manager of Wynnefield Small Cap Value Offshore Fund, Ltd., has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Nelson Obus and Joshua Landes, as principal executive officers of Wynnefield Capital, Inc., have an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Small Cap Value Offshore Fund, Ltd. directly beneficially owns. Does not include 101,589 shares of Common Stock issuable upon conversion of certain shares of Convertible Preferred Stock that are immediately convertible."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person has an indirect beneficial ownership interest in 367,350 shares of Common Stock, which are directly beneficially owned by Wynnefield Capital, Inc. Profit Sharing Plan, as members of a group under Section 13(d) of the Exchange Act. Wynnefield Capital, Inc. Profit Sharing Plan, which maintains offices at the same address as the Reporting Person, is filing this Form jointly with the Reporting Person. Mr. Obus and Mr. Landes, as co-trustees, has the power to vote and dispose of Wynnefield Capital, Inc. Profit Sharing Plan's investments in securities and has an indirect beneficial ownership interest in the shares of Common Stock that Wynnefield Capital, Inc. Profit Sharing Plan directly beneficially owns."}],"balance_after":2607433,"source":{"system":"sec-edgar","filing":"0001104659-24-106795","document":"tm2425764-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899083/000110465924106795/tm2425764-1_4seq1.xml","form_type":"4"}},{"id":1390395,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":86973,"kind":"organization","name":"WYNNEFIELD PARTNERS SMALL CAP VALUE LP I","position":1,"cik":"0001251565","reported_name":"WYNNEFIELD PARTNERS SMALL CAP VALUE LP I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86974,"kind":"organization","name":"WYNNEFIELD PARTNERS SMALL CAP VALUE LP","position":2,"cik":"0000899083","reported_name":"WYNNEFIELD PARTNERS SMALL CAP VALUE LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86975,"kind":"organization","name":"WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD","position":3,"cik":"0001030806","reported_name":"WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86976,"kind":"organization","name":"WYNNEFIELD CAPITAL MANAGEMENT LLC","position":4,"cik":"0001056835","reported_name":"WYNNEFIELD CAPITAL MANAGEMENT LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86977,"kind":"organization","name":"WYNNEFIELD CAPITAL INC","position":5,"cik":"0001251567","reported_name":"WYNNEFIELD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86978,"kind":"organization","name":"Wynnefield Capital, Inc. Profit Sharing Plan","position":6,"cik":"0001289453","reported_name":"Wynnefield Capital, Inc. Profit Sharing Plan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41100,"kind":"person","name":"OBUS NELSON","position":7,"cik":"0001017043","reported_name":"OBUS NELSON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86979,"kind":"person","name":"LANDES JOSHUA","position":8,"cik":"0001251568","reported_name":"LANDES JOSHUA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2024-10-07T20:45:10.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":122930,"price":4.1,"value":504013.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The Reporting Person directly beneficially owns 2,095,783 shares of common stock, $0.001 par value per share (\"Common Stock\") of Lifecore Biomedical, Inc.  Wynnefield Capital Management, LLC, as the sole general partner of the Reporting Person, has an indirect beneficial ownership interest in the shares of Common Stock that the Reporting Person directly beneficially owns. Nelson Obus and Joshua Landes, as co-managing members of Wynnefield Capital Management, LLC, have an indirect beneficial ownership interest in the shares of Common Stock that the Reporting Person directly beneficially owns.  Does not include 243,814 shares of Common Stock issuable upon conversion of certain shares of Series A Convertible Preferred Stock, par value $0.001 per share (the \"Convertible Preferred Stock\") that are immediately convertible."}],"balance_after":2095783,"source":{"system":"sec-edgar","filing":"0001104659-24-106795","document":"tm2425764-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899083/000110465924106795/tm2425764-1_4seq1.xml","form_type":"4"}},{"id":1390371,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37305,"kind":"person","name":"Kiper Christopher S","position":1,"cik":"0001432744","reported_name":"Kiper Christopher S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37299,"kind":"person","name":"Legion Partners Asset Management, LLC","position":2,"cik":"0001560207","reported_name":"Legion Partners Asset Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37300,"kind":"person","name":"Legion Partners, L.P. I","position":3,"cik":"0001595909","reported_name":"Legion Partners, L.P. I","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37301,"kind":"person","name":"Legion Partners, L.P. II","position":4,"cik":"0001618783","reported_name":"Legion Partners, L.P. II","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37303,"kind":"person","name":"Legion Partners, LLC","position":5,"cik":"0001682390","reported_name":"Legion Partners, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37304,"kind":"person","name":"Legion Partners Holdings, LLC","position":6,"cik":"0001682389","reported_name":"Legion Partners Holdings, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37298,"kind":"person","name":"White Raymond T.","position":7,"cik":"0001682494","reported_name":"White Raymond T.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-07T20:33:02.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":152102,"price":4.1,"value":623618.2,"ownership":{"direct":false,"nature":"By: Legion Partners, L.P. II"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Legion Partners, L.P. I (\"Legion Partners I\"), Legion Partners, L.P. II (\"Legion Partners II\"), Legion Partners, LLC (\"General Partner\"), Legion Partners Asset Management, LLC (\"Legion Partners Asset Management\"), Legion Partners Holdings, LLC (\"Legion Partners Holdings\"), Christopher S. Kiper and Raymond White (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that owns more than 10% of Lifecore Biomedical, Inc.'s (the \"Issuer\") outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer, Legion Partners I, Legion Partners II and certain other unaffiliated investors (collectively, the \"Purchasers\"), the Issuer agreed to issue and sell to the Purchasers shares of Common Stock at a price of $4.10 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Securities owned directly by Legion Partners II. General Partner is the general partner of Legion Partners II, Legion Partners Asset Management is the investment advisor of Legion Partners II, Legion Partners Holdings is the sole member of Legion Partners Asset Management and managing member of General Partner, and each of Messrs. Kiper and White are managing directors of Legion Partners Asset Management and managing members of Legion Partners Holdings. As a result of these relationships, General Partner, Legion Partners Asset Management, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners II."}],"balance_after":319286,"source":{"system":"sec-edgar","filing":"0000921895-24-002254","document":"form409050032_10072024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000092189524002254/form409050032_10072024.xml","form_type":"4"}},{"id":1390370,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37305,"kind":"person","name":"Kiper Christopher S","position":1,"cik":"0001432744","reported_name":"Kiper Christopher S","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37299,"kind":"person","name":"Legion Partners Asset Management, LLC","position":2,"cik":"0001560207","reported_name":"Legion Partners Asset Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37300,"kind":"person","name":"Legion Partners, L.P. I","position":3,"cik":"0001595909","reported_name":"Legion Partners, L.P. I","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37301,"kind":"person","name":"Legion Partners, L.P. II","position":4,"cik":"0001618783","reported_name":"Legion Partners, L.P. II","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37303,"kind":"person","name":"Legion Partners, LLC","position":5,"cik":"0001682390","reported_name":"Legion Partners, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37304,"kind":"person","name":"Legion Partners Holdings, LLC","position":6,"cik":"0001682389","reported_name":"Legion Partners Holdings, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37298,"kind":"person","name":"White Raymond T.","position":7,"cik":"0001682494","reported_name":"White Raymond T.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-07T20:33:02.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":1311312,"price":4.1,"value":5376379.2,"ownership":{"direct":false,"nature":"By: Legion Partners, L.P. I"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Legion Partners, L.P. I (\"Legion Partners I\"), Legion Partners, L.P. II (\"Legion Partners II\"), Legion Partners, LLC (\"General Partner\"), Legion Partners Asset Management, LLC (\"Legion Partners Asset Management\"), Legion Partners Holdings, LLC (\"Legion Partners Holdings\"), Christopher S. Kiper and Raymond White (collectively, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that owns more than 10% of Lifecore Biomedical, Inc.'s (the \"Issuer\") outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer, Legion Partners I, Legion Partners II and certain other unaffiliated investors (collectively, the \"Purchasers\"), the Issuer agreed to issue and sell to the Purchasers shares of Common Stock at a price of $4.10 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities owned directly by Legion Partners I. General Partner is the general partner of Legion Partners I, Legion Partners Asset Management is the investment advisor of Legion Partners I, Legion Partners Holdings is the sole member of Legion Partners Asset Management and managing member of General Partner, and each of Messrs. Kiper and White are managing directors of Legion Partners Asset Management and managing members of Legion Partners Holdings. As a result of these relationships, General Partner, Legion Partners Asset Management, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners I."}],"balance_after":4084268,"source":{"system":"sec-edgar","filing":"0000921895-24-002254","document":"form409050032_10072024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000092189524002254/form409050032_10072024.xml","form_type":"4"}},{"id":1407078,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41098,"kind":"person","name":"Antunes Humberto Calheiros","position":1,"cik":"0001800145","reported_name":"Antunes Humberto Calheiros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T19:24:20.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":24554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amendment includes 3,000 shares that were inadvertently omitted from the Form 3 filed on behalf of the reporting person on August 21, 2024."}],"balance_after":27554,"source":{"system":"sec-edgar","filing":"0001628280-24-040456","document":"wk-form4a_1726514653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024040456/wk-form4a_1726514653.xml","form_type":"4/A","original_submission_date":"2024-08-21"}},{"id":1414547,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2024-09-05T20:18:49.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock prices."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones."}],"balance_after":0,"derivative":{"expiration_date":"2029-09-03","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001628280-24-039547","document":"wk-form4_1725567522.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024039547/wk-form4_1725567522.xml","form_type":"4"}},{"id":1414546,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":75809,"kind":"person","name":"Lake Ryan David","position":1,"cik":"0001450325","reported_name":"Lake Ryan David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-05T20:18:49.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":262500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":262500,"source":{"system":"sec-edgar","filing":"0001628280-24-039547","document":"wk-form4_1725567522.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024039547/wk-form4_1725567522.xml","form_type":"4"}},{"id":1425909,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41097,"kind":"person","name":"Johnson Paul Harold","position":1,"cik":"0002034858","reported_name":"Johnson Paul Harold","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-22T19:00:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":24554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024)."}],"balance_after":24554,"source":{"system":"sec-edgar","filing":"0001628280-24-038196","document":"wk-form4_1724353252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024038196/wk-form4_1724353252.xml","form_type":"4"}},{"id":1426852,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41098,"kind":"person","name":"Antunes Humberto Calheiros","position":1,"cik":"0001800145","reported_name":"Antunes Humberto Calheiros","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-21T23:55:22.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":24554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024)."}],"balance_after":24554,"source":{"system":"sec-edgar","filing":"0001628280-24-038091","document":"wk-form4_1724284516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024038091/wk-form4_1724284516.xml","form_type":"4"}},{"id":1426851,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-21T23:54:04.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":24554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024)."}],"balance_after":24554,"source":{"system":"sec-edgar","filing":"0001628280-24-038090","document":"wk-form4_1724284438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024038090/wk-form4_1724284438.xml","form_type":"4"}},{"id":1426850,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37594,"kind":"person","name":"Korenberg Matthew E","position":1,"cik":"0001649903","reported_name":"Korenberg Matthew E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-21T23:52:33.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":24554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024)."}],"balance_after":24554,"source":{"system":"sec-edgar","filing":"0001628280-24-038088","document":"wk-form4_1724284348.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024038088/wk-form4_1724284348.xml","form_type":"4"}},{"id":1457098,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":911,"kind":"person","name":"Barbarosh Craig A.","position":1,"cik":"0001472457","reported_name":"Barbarosh Craig A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-10T23:53:47.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":false,"nature":"In Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration."}],"balance_after":88073,"source":{"system":"sec-edgar","filing":"0001628280-24-031636","document":"wk-form4_1720655620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024031636/wk-form4_1720655620.xml","form_type":"4"}},{"id":1457096,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":81019,"kind":"person","name":"Calloway Nathaniel","position":1,"cik":"0001952771","reported_name":"Calloway Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-10T23:52:03.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration."}],"balance_after":58069,"source":{"system":"sec-edgar","filing":"0001628280-24-031634","document":"wk-form4_1720655516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024031634/wk-form4_1720655516.xml","form_type":"4"}},{"id":1457097,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":89075,"kind":"person","name":"Diradoorian Raymond H","position":1,"cik":"0001352121","reported_name":"Diradoorian Raymond H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-10T23:49:30.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration."}],"balance_after":69978,"source":{"system":"sec-edgar","filing":"0001628280-24-031632","document":"wk-form4_1720655363.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024031632/wk-form4_1720655363.xml","form_type":"4"}},{"id":1457095,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37453,"kind":"person","name":"EDWARDS JEFFREY L","position":1,"cik":"0001190642","reported_name":"EDWARDS JEFFREY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-10T23:46:15.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration."}],"balance_after":79667,"source":{"system":"sec-edgar","filing":"0001628280-24-031630","document":"wk-form4_1720655169.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024031630/wk-form4_1720655169.xml","form_type":"4"}},{"id":1457094,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41095,"kind":"person","name":"HOUDE LOVAS KATRINA","position":1,"cik":"0001269294","reported_name":"HOUDE LOVAS KATRINA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-10T23:44:23.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration."}],"balance_after":89906,"source":{"system":"sec-edgar","filing":"0001628280-24-031628","document":"wk-form4_1720655057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024031628/wk-form4_1720655057.xml","form_type":"4"}},{"id":1457078,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41100,"kind":"person","name":"OBUS NELSON","position":1,"cik":"0001017043","reported_name":"OBUS NELSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-10T23:43:07.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration."}],"balance_after":118687,"source":{"system":"sec-edgar","filing":"0001628280-24-031626","document":"wk-form4_1720654981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024031626/wk-form4_1720654981.xml","form_type":"4"}},{"id":1457077,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41099,"kind":"person","name":"Schechter Joshua","position":1,"cik":"0001336601","reported_name":"Schechter Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-10T23:41:22.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration."}],"balance_after":87667,"source":{"system":"sec-edgar","filing":"0001628280-24-031624","document":"wk-form4_1720654875.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024031624/wk-form4_1720654875.xml","form_type":"4"}},{"id":1457076,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37305,"kind":"person","name":"Kiper Christopher S","position":1,"cik":"0001432744","reported_name":"Kiper Christopher S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37299,"kind":"person","name":"Legion Partners Asset Management, LLC","position":2,"cik":"0001560207","reported_name":"Legion Partners Asset Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37300,"kind":"person","name":"Legion Partners, L.P. I","position":3,"cik":"0001595909","reported_name":"Legion Partners, L.P. I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37301,"kind":"person","name":"Legion Partners, L.P. II","position":4,"cik":"0001618783","reported_name":"Legion Partners, L.P. II","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37303,"kind":"person","name":"Legion Partners, LLC","position":5,"cik":"0001682390","reported_name":"Legion Partners, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37304,"kind":"person","name":"Legion Partners Holdings, LLC","position":6,"cik":"0001682389","reported_name":"Legion Partners Holdings, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37298,"kind":"person","name":"White Raymond T.","position":7,"cik":"0001682494","reported_name":"White Raymond T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-10T20:10:19.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Legion Partners, L.P. I, Legion Partners, L.P. II, Legion Partners, LLC, Legion Partners Asset Management, LLC (\"Legion Partners Asset Management\"), Legion Partners Holdings, LLC, Christopher S. Kiper and Raymond White (collectively, the \"Reporting Persons\"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The securities held by Mr. Kiper as described in footnote (4), including the 30,000 restricted stock units described herein, are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the \"Issuer\") on a 1 for 1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"The restricted stock units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from grant date)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the \"Issuer\") on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2025 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from grant date)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The securities held by Mr. Kiper as described in footnote (4), including the 30,000 restricted stock units described herein, are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"The securities held by Mr. Kiper as described in footnote (4), including the 30,000 restricted stock units described herein, are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."}],"balance_after":58069,"source":{"system":"sec-edgar","filing":"0000921895-24-001545","document":"form409050032_07102024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000092189524001545/form409050032_07102024.xml","form_type":"4"}},{"id":1506031,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2024-05-22T21:48:54.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The performance-based restricted stock units vest, if it all, based on the Issuer's achievement of certain stock prices."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones."}],"balance_after":0,"derivative":{"expiration_date":"2029-05-20","underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001628280-24-024782","document":"wk-form4_1716414520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024024782/wk-form4_1716414520.xml","form_type":"4"}},{"id":1506030,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-22T21:48:54.000Z","date":"2024-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":8975,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":516025,"source":{"system":"sec-edgar","filing":"0001628280-24-024782","document":"wk-form4_1716414520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024024782/wk-form4_1716414520.xml","form_type":"4"}},{"id":1506029,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":45420,"kind":"person","name":"Josephs Paul","position":1,"cik":"0002022547","reported_name":"Josephs Paul","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-22T21:48:54.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":525000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":525000,"source":{"system":"sec-edgar","filing":"0001628280-24-024782","document":"wk-form4_1716414520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024024782/wk-form4_1716414520.xml","form_type":"4"}},{"id":1662580,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41099,"kind":"person","name":"Schechter Joshua","position":1,"cik":"0001336601","reported_name":"Schechter Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-02-03T00:02:00.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":9554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on February 1, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-01","underlying":"Common Stock","underlying_shares":9554},"source":{"system":"sec-edgar","filing":"0001628280-24-003144","document":"wk-form4_1706918511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003144/wk-form4_1706918511.xml","form_type":"4"}},{"id":1662579,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41099,"kind":"person","name":"Schechter Joshua","position":1,"cik":"0001336601","reported_name":"Schechter Joshua","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-03T00:02:00.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":9554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":57667,"source":{"system":"sec-edgar","filing":"0001628280-24-003144","document":"wk-form4_1706918511.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003144/wk-form4_1706918511.xml","form_type":"4"}},{"id":1662578,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":81019,"kind":"person","name":"Calloway Nathaniel","position":1,"cik":"0001952771","reported_name":"Calloway Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-02T23:41:59.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":3981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on February 1, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-01","underlying":"Common Stock","underlying_shares":3981},"source":{"system":"sec-edgar","filing":"0001628280-24-003139","document":"wk-form4_1706917311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003139/wk-form4_1706917311.xml","form_type":"4"}},{"id":1662577,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":81019,"kind":"person","name":"Calloway Nathaniel","position":1,"cik":"0001952771","reported_name":"Calloway Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T23:41:59.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":3981,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":28069,"source":{"system":"sec-edgar","filing":"0001628280-24-003139","document":"wk-form4_1706917311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003139/wk-form4_1706917311.xml","form_type":"4"}},{"id":1662576,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41100,"kind":"person","name":"OBUS NELSON","position":1,"cik":"0001017043","reported_name":"OBUS NELSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-02T23:40:32.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":9554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on February 1, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-01","underlying":"Common Stock","underlying_shares":9554},"source":{"system":"sec-edgar","filing":"0001628280-24-003137","document":"wk-form4_1706917221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003137/wk-form4_1706917221.xml","form_type":"4"}},{"id":1662575,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41100,"kind":"person","name":"OBUS NELSON","position":1,"cik":"0001017043","reported_name":"OBUS NELSON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T23:40:32.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":9554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":88687,"source":{"system":"sec-edgar","filing":"0001628280-24-003137","document":"wk-form4_1706917221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003137/wk-form4_1706917221.xml","form_type":"4"}},{"id":1662574,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37453,"kind":"person","name":"EDWARDS JEFFREY L","position":1,"cik":"0001190642","reported_name":"EDWARDS JEFFREY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-02T23:35:44.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":9554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on February 1, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-01","underlying":"Common Stock","underlying_shares":9554},"source":{"system":"sec-edgar","filing":"0001628280-24-003134","document":"wk-form4_1706916917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003134/wk-form4_1706916917.xml","form_type":"4"}},{"id":1662573,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37453,"kind":"person","name":"EDWARDS JEFFREY L","position":1,"cik":"0001190642","reported_name":"EDWARDS JEFFREY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T23:35:44.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":9554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":49667,"source":{"system":"sec-edgar","filing":"0001628280-24-003134","document":"wk-form4_1706916917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003134/wk-form4_1706916917.xml","form_type":"4"}},{"id":1662572,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":89075,"kind":"person","name":"Diradoorian Raymond H","position":1,"cik":"0001352121","reported_name":"Diradoorian Raymond H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-02T23:33:41.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":9554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on February 1, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-01","underlying":"Common Stock","underlying_shares":9554},"source":{"system":"sec-edgar","filing":"0001628280-24-003132","document":"wk-form4_1706916810.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003132/wk-form4_1706916810.xml","form_type":"4"}},{"id":1662571,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":89075,"kind":"person","name":"Diradoorian Raymond H","position":1,"cik":"0001352121","reported_name":"Diradoorian Raymond H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T23:33:41.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":9554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":39978,"source":{"system":"sec-edgar","filing":"0001628280-24-003132","document":"wk-form4_1706916810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003132/wk-form4_1706916810.xml","form_type":"4"}},{"id":1662570,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41095,"kind":"person","name":"HOUDE LOVAS KATRINA","position":1,"cik":"0001269294","reported_name":"HOUDE LOVAS KATRINA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-02T23:31:43.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":9554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on February 1, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-01","underlying":"Common Stock","underlying_shares":9554},"source":{"system":"sec-edgar","filing":"0001628280-24-003128","document":"wk-form4_1706916694.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003128/wk-form4_1706916694.xml","form_type":"4"}},{"id":1662569,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":41095,"kind":"person","name":"HOUDE LOVAS KATRINA","position":1,"cik":"0001269294","reported_name":"HOUDE LOVAS KATRINA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T23:31:43.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":9554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":59906,"source":{"system":"sec-edgar","filing":"0001628280-24-003128","document":"wk-form4_1706916694.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003128/wk-form4_1706916694.xml","form_type":"4"}},{"id":1662568,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":911,"kind":"person","name":"Barbarosh Craig A.","position":1,"cik":"0001472457","reported_name":"Barbarosh Craig A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-02-02T23:30:17.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":9554,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"In Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted Stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on February 1, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-01","underlying":"Common Stock","underlying_shares":9554},"source":{"system":"sec-edgar","filing":"0001628280-24-003126","document":"wk-form4_1706916605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003126/wk-form4_1706916605.xml","form_type":"4"}},{"id":1662567,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":911,"kind":"person","name":"Barbarosh Craig A.","position":1,"cik":"0001472457","reported_name":"Barbarosh Craig A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T23:30:17.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":9554,"ownership":{"direct":false,"nature":"In Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted Stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":58073,"source":{"system":"sec-edgar","filing":"0001628280-24-003126","document":"wk-form4_1706916605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024003126/wk-form4_1706916605.xml","form_type":"4"}},{"id":1674550,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":95028,"kind":"person","name":"Morberg John D","position":1,"cik":"0001345964","reported_name":"Morberg John D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-22T19:26:42.000Z","date":"2024-01-18","kind":"exercise","planned":false,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on January 18, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-01-18","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-24-001842","document":"wk-form4_1705951591.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024001842/wk-form4_1705951591.xml","form_type":"4"}},{"id":1674549,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":95028,"kind":"person","name":"Morberg John D","position":1,"cik":"0001345964","reported_name":"Morberg John D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-22T19:26:42.000Z","date":"2024-01-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":6283,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":125617,"source":{"system":"sec-edgar","filing":"0001628280-24-001842","document":"wk-form4_1705951591.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024001842/wk-form4_1705951591.xml","form_type":"4"}},{"id":1674548,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":95028,"kind":"person","name":"Morberg John D","position":1,"cik":"0001345964","reported_name":"Morberg John D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-22T19:26:42.000Z","date":"2024-01-18","kind":"exercise","planned":false,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":131900,"source":{"system":"sec-edgar","filing":"0001628280-24-001842","document":"wk-form4_1705951591.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024001842/wk-form4_1705951591.xml","form_type":"4"}},{"id":1681917,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":81019,"kind":"person","name":"Calloway Nathaniel","position":1,"cik":"0001952771","reported_name":"Calloway Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-01-11T00:14:35.000Z","date":"2024-01-09","kind":"exercise","planned":false,"acquired":false,"shares":5906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested on January 9, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-01-09","underlying":"Common Stock","underlying_shares":5906},"source":{"system":"sec-edgar","filing":"0001628280-24-001074","document":"wk-form4_1704932063.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024001074/wk-form4_1704932063.xml","form_type":"4"}},{"id":1681916,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":81019,"kind":"person","name":"Calloway Nathaniel","position":1,"cik":"0001952771","reported_name":"Calloway Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-11T00:14:35.000Z","date":"2024-01-09","kind":"exercise","planned":false,"acquired":true,"shares":5906,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."}],"balance_after":24088,"source":{"system":"sec-edgar","filing":"0001628280-24-001074","document":"wk-form4_1704932063.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828024001074/wk-form4_1704932063.xml","form_type":"4"}},{"id":1868046,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":37305,"kind":"person","name":"Kiper Christopher S","position":1,"cik":"0001432744","reported_name":"Kiper Christopher S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37299,"kind":"person","name":"Legion Partners Asset Management, LLC","position":2,"cik":"0001560207","reported_name":"Legion Partners Asset Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37300,"kind":"person","name":"Legion Partners, L.P. I","position":3,"cik":"0001595909","reported_name":"Legion Partners, L.P. I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37301,"kind":"person","name":"Legion Partners, L.P. II","position":4,"cik":"0001618783","reported_name":"Legion Partners, L.P. II","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37303,"kind":"person","name":"Legion Partners, LLC","position":5,"cik":"0001682390","reported_name":"Legion Partners, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37304,"kind":"person","name":"Legion Partners Holdings, LLC","position":6,"cik":"0001682389","reported_name":"Legion Partners Holdings, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37298,"kind":"person","name":"White Raymond T.","position":7,"cik":"0001682494","reported_name":"White Raymond T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:17:24.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":18182,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Legion Partners, L.P. I, Legion Partners, L.P. II, Legion Partners, LLC, Legion Partners Asset Management, LLC (\"Legion Partners Asset Management\"), Legion Partners Holdings, LLC, Christopher S. Kiper and Raymond White (collectively, the \"Reporting Persons\"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"shares","element":"transactionShares","label":"F4","text":"Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the \"Issuer\") on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from grant date)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"The securities described in footnotes (2) and (3) represent securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management."}],"balance_after":28069,"source":{"system":"sec-edgar","filing":"0000921895-23-001426","document":"form409050032_06052023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000092189523001426/form409050032_06052023.xml","form_type":"4"}},{"id":1868045,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":911,"kind":"person","name":"Barbarosh Craig A.","position":1,"cik":"0001472457","reported_name":"Barbarosh Craig A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T19:32:10.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":18182,"ownership":{"direct":false,"nature":"In Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date)."}],"balance_after":48519,"source":{"system":"sec-edgar","filing":"0001628280-23-020846","document":"wk-form4_1685993517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828023020846/wk-form4_1685993517.xml","form_type":"4"}},{"id":1868044,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":89075,"kind":"person","name":"Diradoorian Raymond H","position":1,"cik":"0001352121","reported_name":"Diradoorian Raymond H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T19:30:25.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":18182,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date)."}],"balance_after":30424,"source":{"system":"sec-edgar","filing":"0001628280-23-020843","document":"wk-form4_1685993416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828023020843/wk-form4_1685993416.xml","form_type":"4"}},{"id":1868043,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":112753,"kind":"person","name":"Hall James G","position":1,"cik":"0001368626","reported_name":"Hall James G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-05T19:27:49.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Restricted Stock Units will vest on the 3rd anniversary of the grant date or if earlier, upon a Change in Control."}],"balance_after":276096,"source":{"system":"sec-edgar","filing":"0001628280-23-020841","document":"wk-form4_1685993261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828023020841/wk-form4_1685993261.xml","form_type":"4"}},{"id":1868042,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":112753,"kind":"person","name":"Hall James G","position":1,"cik":"0001368626","reported_name":"Hall James G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-05T19:27:49.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted Stock Units will vest on the 3rd anniversary of the grant date."}],"balance_after":201096,"source":{"system":"sec-edgar","filing":"0001628280-23-020841","document":"wk-form4_1685993261.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828023020841/wk-form4_1685993261.xml","form_type":"4"}},{"id":1868041,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":95028,"kind":"person","name":"Morberg John D","position":1,"cik":"0001345964","reported_name":"Morberg John D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-05T19:24:12.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Restricted Stock Units will vest on the 3rd anniversary of the grant date or if earlier, upon a Change in Control."}],"balance_after":114400,"source":{"system":"sec-edgar","filing":"0001628280-23-020839","document":"wk-form4_1685993042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828023020839/wk-form4_1685993042.xml","form_type":"4"}},{"id":1868040,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":95028,"kind":"person","name":"Morberg John D","position":1,"cik":"0001345964","reported_name":"Morberg John D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-05T19:24:12.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted Stock Units will vest on the 3rd anniversary of the grant date."}],"balance_after":64400,"source":{"system":"sec-edgar","filing":"0001628280-23-020839","document":"wk-form4_1685993042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828023020839/wk-form4_1685993042.xml","form_type":"4"}},{"id":1868039,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":81019,"kind":"person","name":"Calloway Nathaniel","position":1,"cik":"0001952771","reported_name":"Calloway Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T19:19:44.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":18182,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted Stock Units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from Grant Date)."}],"balance_after":18182,"source":{"system":"sec-edgar","filing":"0001628280-23-020835","document":"wk-form4_1685992772.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828023020835/wk-form4_1685992772.xml","form_type":"4"}}],"next_cursor":"2023-06-05T19:19:44.000000Z,1868039"}